VXRT
Vaxart (VXRT)
$69
About Vaxart (VXRT)
Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$0.84
52 Week Low
$0.26
Market cap
173.3M
Dividend yield
0.00%
Volume
--
Avg. volume
717,668
P/E ratio
12.14
Vaxart News
Details
Daily high
--
Daily low
--
Price at open
--
52 Week High
$0.84
52 Week Low
$0.26
Market cap
173.3M
Dividend yield
0.00%
Volume
--
Avg. volume
717,668
P/E ratio
12.14